Bard Davol designed its Kugel Patch for minimally-invasive hernia mesh surgery. It had a defective ring that could break and puncture organs. The problems led to several recalls and thousands of lawsuits. By 2018, Bard had stopped marketing the Kugel Hernia Patch in the U.S.
If you or a loved one suffered complications or injury after hernia mesh surgery, you may have legal options.
The Kugel Patch was a line of hernia mesh products Bard Davol manufactured starting in the 1990s. Bard received reports that the Kugel Patch was failing as early as 2002. The failure rate appeared higher than normal. But the company waited almost three years before recalling its mesh.
Bard finally recalled more than 137,000 of the devices between 2005 and 2007. A defective part in some of the meshes could break and puncture internal organs or other tissue.
More than 3,000 people sued over Kugel Patch injuries. Bard paid more than $180 million to settle the Kugel Patch lawsuits in 2011.
A 2018 search showed Bard no longer lists the Kugel Hernia Patch in its products catalogue.
Kugel Patches were double-layer polypropylene hernia meshes. Polypropylene is a type of plastic. Many manufacturers make mesh from this plastic.
Bard Davol designed the mesh for minimally-invasive laparoscopic hernia repairs.
A surgeon folded the Kugel Patch to insert it through small incisions. A “memory recoil ring” built into the mesh caused the patch to spring open to its full shape and size.
The U.S. Food and Drug Administration approved the Kugel Hernia Patch in 1996. Bard named the devices after their developer, Dr. Robert D. Kugel.
In some patients, the device’s ring broke or bent. This caused the patch to move from where surgeons implanted it. The migrations resulted in bowel obstructions and punctures.
Bard saw a flurry of complaints starting in June 2005. Over a three month period, the company received 10 reports that the rings broke. Six of the reports came from Germany. Half of those came from the same doctor.
Bard blamed surgeons for not inserting the patch correctly. The company temporarily stopped producing its large Kugel Patch version in mid-2005. Bard reworked its implanting instructions. And the company held training sessions for surgeons.
In December 2005, Bard ran tests on the rings. The results pinned the problem on the ring’s design. That same month, Bard recalled three Kugel Patch versions
Bard issued the first in its series of Kugel Patch recalls in December 2005. The recall notice warned the ring defect could cause bowel perforations and fistulas. The first recall affected more than 37,000 units. The FDA declared it a Class I recall – the agency’s most serious type.
Bard expanded the recall to two other products five days later. The three products recalled in 2005 had accounted for $11 million in sales for Bard that year.
The company issued more recall notices for different versions of the Kugel Patch in 2007. Bard recalled more than 137,000 units in all.
|Recall Date||Number of Kugel Patches Recalled|
|Dec. 22, 2005||37,761|
|Dec. 27, 2005 (3 versions recalled)||50,506|
|Jan. 10, 2007 (2 versions recalled)||49,184|
FDA inspectors visited Bard Davol’s Kugel Patch manufacturing plant in early 2006. The inspectors found several problems with how Bard investigated complaints.
Device makers must report complaints about their products to the FDA. The agency claimed Bard understated how severe device-related complications actually were. Inspectors pointed to three reports involving patient injuries and one possible device-related death.
More than 3,000 people filed lawsuits over Kugel Patch injuries. A federal panel combined them into a multidistrict litigation (MDL). MDLs allow several similar cases to move more efficiently through the legal process.
Bard won the first trial in the MDL. But the jury in the second trial found the Kugel Patch was defective. It awarded a $1.5 million verdict to plaintiff Christopher Thorpe in 2010.
The following year, Bard settled more than 2,600 lawsuits for $184 million.
Bard Davol also faced a Canadian Kugel Patch class action lawsuit. The company settled that suit for nearly $1.4 million in 2014.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(844) 807-8916